HDAC-42 is primarily used in research and development within the field of oncology. It functions as a histone deacetylase inhibitor, which plays a crucial role in regulating gene expression by modifying chromatin structure. This mechanism makes it a potential candidate for cancer therapy, as it can induce cell cycle arrest, differentiation, and apoptosis in various cancer cell lines. Researchers are particularly interested in its ability to target specific pathways involved in tumor growth and metastasis. Additionally, HDAC-42 is being studied for its potential to enhance the efficacy of other anticancer agents when used in combination therapies. Its application extends to preclinical studies aimed at understanding epigenetic modifications and their impact on cancer progression.